Innate Immunotherapeutics Limited (ASX Code:IIL), together with a number of Australian, Canadian, and Danish scientific collaborators presented five posters at last week’s American Academy of Neurology (AAN) Annual Meeting held in Boston.
In parallel with the AAN meeting the Company hosted a meeting of clinical and scientific key opinion leaders in the field of progressive multiple sclerosis to provide an update on the MIS416 clinical development programme and latest insights into the drug's mechanism of action. This presentation is attached.
For further information please download PDF attached:
Download this document
